With backing from Bayer and others, the US-based venture will develop iPSC therapies for cardiovascular and neurodegenerative diseases; other notable new financings involve Cerevance, Goldfinch Bio, NeuroPharma and Tenaya. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced November through December 2016.